

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Evaluation

Equality impact assessment – Scoping

Baxdrostat for treating uncontrolled or resistant hypertension ID6623

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

During the writing of the draft scope, it was recognised that there is some evidence to suggest that blood pressure is less likely to be controlled by medication for people in African or African Caribbean groups, which was highlighted in the scope.

One commenter noted the prevalence of later-stage CKD, in people with hypertension is higher in South-Asian populations.

One commenter noted treatments to target blood pressure and ACE-I/ARB prescribing was lowest in the Black population.

One commenter noted some ethnic minority groups may also progress faster to kidney failure and may face longer waits for transplantation.

One commenter noted people from lower socio-economic backgrounds may be less able to make changes to diet, exercise or access to regular support for smoking cessation.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

Race is a protected characteristic under equalities legislation. The committee will consider the issues during development of the guidance. If

a positive recommendation is reached, the committee will need to consider any equality issues related to eligibility criteria in its decision-making

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?

No

Approved by Associate Director (name): Ross Dent

Date: 27/03/2026